Literature DB >> 7493026

Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy.

G Bonne1, L Carrier, J Bercovici, C Cruaud, P Richard, B Hainque, M Gautel, S Labeit, M James, J Beckmann, J Weissenbach, H P Vosberg, M Fiszman, M Komajda, K Schwartz.   

Abstract

Familial hypertrophic cardiomyopathy (FHC) is an autosomal dominant disease characterized by a ventricular hypertrophy predominantly affecting the interventricular septum and associated with a large extent of myocardial and myofibrillar disarray. It is the most common cause of sudden death in the young. In the four disease loci found, three genes have been identified which code for beta-myosin heavy chain, cardiac troponin T and alpha-tropomyosin. Recently the human cardiac myosin binding protein-C (MyBP-C) gene was mapped to chromosome 11p11.2 (ref. 8), making this gene a good candidate for the fourth locus, CMH4 (ref. 5). Indeed, MyBP-C is a substantial component of the myofibrils that interacts with several proteins of the thick filament of the sarcomere. In two unrelated French families linked to CMH4, we found a mutation in a splice acceptor site of the MyBP-C gene, which causes the skipping of the associated exon and could produce truncated cardiac MyBP-Cs. Mutations in the cardiac MyBP-C gene likely cause chromosome 11-linked hypertrophic cardiomyopathy, further supporting the hypothesis that hypertrophic cardiomyopathy results from mutations in genes encoding contractile proteins.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493026     DOI: 10.1038/ng1295-438

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  110 in total

1.  Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy.

Authors:  K Prasad; J Atherton; G C Smith; W J McKenna; M P Frenneaux; P Nihoyannopoulos
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

2.  On genetic and phenotypic variability of hypertrophic cardiomyopathy: nature versus nurture.

Authors:  A J Marian
Journal:  J Am Coll Cardiol       Date:  2001-08       Impact factor: 24.094

Review 3.  Modifier genes for hypertrophic cardiomyopathy.

Authors:  A J Marian
Journal:  Curr Opin Cardiol       Date:  2002-05       Impact factor: 2.161

4.  Experimental Modeling Supports a Role for MyBP-HL as a Novel Myofilament Component in Arrhythmia and Dilated Cardiomyopathy.

Authors:  David Y Barefield; Megan J Puckelwartz; Ellis Y Kim; Lisa D Wilsbacher; Andy H Vo; Emily A Waters; Judy U Earley; Michele Hadhazy; Lisa Dellefave-Castillo; Lorenzo L Pesce; Elizabeth M McNally
Journal:  Circulation       Date:  2017-08-04       Impact factor: 29.690

Review 5.  The molecular genetic basis for hypertrophic cardiomyopathy.

Authors:  A J Marian; R Roberts
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

6.  To screen or not is not the question--it is when and how to screen.

Authors:  A J Marian; R Roberts
Journal:  Circulation       Date:  2003-05-06       Impact factor: 29.690

7.  Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies.

Authors:  Kenneth R Chien
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 8.  Mechanical and energetic consequences of HCM-causing mutations.

Authors:  Cecilia Ferrantini; Alexandra Belus; Nicoletta Piroddi; Beatrice Scellini; Chiara Tesi; Corrado Poggesi
Journal:  J Cardiovasc Transl Res       Date:  2009-10-09       Impact factor: 4.132

Review 9.  MYBPC3's alternate ending: consequences and therapeutic implications of a highly prevalent 25 bp deletion mutation.

Authors:  Diederik W D Kuster; Sakthivel Sadayappan
Journal:  Pflugers Arch       Date:  2013-12-11       Impact factor: 3.657

10.  Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.

Authors:  Diederik W D Kuster; Thomas L Lynch; David Y Barefield; Mayandi Sivaguru; Gina Kuffel; Michael J Zilliox; Kyoung Hwan Lee; Roger Craig; Rajasekaran Namakkal-Soorappan; Sakthivel Sadayappan
Journal:  Cardiovasc Res       Date:  2019-12-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.